TWI517793B - Contains the composition of imidazole peptides and quercetin glycosides - Google Patents

Contains the composition of imidazole peptides and quercetin glycosides Download PDF

Info

Publication number
TWI517793B
TWI517793B TW102106731A TW102106731A TWI517793B TW I517793 B TWI517793 B TW I517793B TW 102106731 A TW102106731 A TW 102106731A TW 102106731 A TW102106731 A TW 102106731A TW I517793 B TWI517793 B TW I517793B
Authority
TW
Taiwan
Prior art keywords
composition
glycoside
imidazole
peptide
imidazole peptide
Prior art date
Application number
TW102106731A
Other languages
Chinese (zh)
Other versions
TW201347681A (en
Inventor
Nozomi Kitahara
Aki Tsujimoto
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of TW201347681A publication Critical patent/TW201347681A/en
Application granted granted Critical
Publication of TWI517793B publication Critical patent/TWI517793B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/86—Addition of bitterness inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Description

含有咪唑胜肽與槲黃素配糖體之組成物 Composition containing imidazole peptide and quercetin glycoside

本發明係有關一種含有咪唑胜肽與槲黃素配糖體之組成物。具體而言，係有關一種改善起因於槲黃素配糖體之異味的組成物。而且，本發明有關一種改善槲黃素配糖體之異味的方法。 The present invention relates to a composition comprising an imidazole peptide and a quercetin glycoside. Specifically, it relates to a composition for improving the odor caused by the flavonoid glycoside. Moreover, the present invention relates to a method for improving the odor of a flavonoid glycoside.

大多數含於呋喃型化合物(furanoid)之一種的含於洋蔥或蕎麥等植物中之槲黃素及其配糖體，已知會呈現各種生理作用。有關槲黃素及其配糖體，直至目前報告有抗發炎作用、抗氧化作用、血管收縮作用、增強毛細管壁之作用等，使用於食品、醫藥品、化妝品等用途。另外，近年來亦報告可抑制蛋白質分解(非專利文獻1)。然而，槲黃素配糖體中具有獨特的香味(特別是苦味)，以飲食品等形態提供時，其苦味會有問題。遮蔽該苦味之方法，已知有藉由含有硫酸軟骨素之軟骨水系溶劑萃取物的方法(專利文獻1)。 Most of the flavin and its glycoside contained in plants such as onions or buckwheat, which are contained in one of the furanoid compounds, are known to exhibit various physiological effects. Regarding quercetin and its glycoside, it has been reported to have anti-inflammatory effects, anti-oxidation effects, vasoconstriction effects, and enhancement of capillary wall functions, and is used for foods, pharmaceuticals, cosmetics, and the like. In addition, it has been reported in recent years that protein decomposition can be suppressed (Non-Patent Document 1). However, the flavonoid glycoside has a unique flavor (especially bitterness), and when it is provided in the form of a food or drink, the bitterness is problematic. A method of masking the bitterness is known as a method of extracting a cartilage aqueous solvent containing chondroitin sulfate (Patent Document 1).

另外，咪唑胜肽含於魚肉萃取物或雞胸肉萃取物中，藉由攝取此等，可確認抗氧化、減低眼睛疲勞、抑制血糖 值上昇、促進吸收鐵等之廣泛效果。此外，由於咪唑胜肽大多含於骨骼肌中，與肌肉中之含量有關，可發揮肌力(專利文獻2)。 In addition, the imidazole peptide is contained in fish extract or chicken breast extract, and by ingesting it, it is possible to confirm antioxidant, reduce eye fatigue, and suppress blood sugar. The value rises and promotes the wide-ranging effects of absorbing iron. In addition, since the imidazole peptide is mostly contained in skeletal muscle, it is related to the content in the muscle, and muscle strength can be exerted (Patent Document 2).

〔先前技術文獻〕 [Previous Technical Literature] 〔專利文獻〕 [Patent Document]

〔專利文獻1〕日本專利4652486號公報 [Patent Document 1] Japanese Patent No. 4652486

〔專利文獻2〕日本特開2008-143788號公報 [Patent Document 2] Japanese Patent Laid-Open Publication No. 2008-143788

〔非專利文獻〕 [Non-patent literature]

〔非專利文獻1〕Molecular and Cellular Biochemistry 243: 153-160, 2003 [Non-Patent Document 1] Molecular and Cellular Biochemistry 243: 153-160, 2003

如上所述，有關具有獨特香味(特別是苦味)之槲黃素配糖體，於經口攝取時其味道或適口性常有問題。特別是於日常經口攝取槲黃素配糖體作為補充劑等機能性食品時，必須抑制槲黃素配糖體特有的香味，要求開發抑制起因於槲黃素配糖體的香味之飲食物。 As described above, the flavonoid glycoside having a unique aroma (especially bitterness) is often problematic in taste or palatability upon oral ingestion. In particular, when daily ingestion of a flavonoid glycoside as a functional food such as a supplement, it is necessary to suppress the flavor unique to the flavonoid glycoside, and it is required to develop a food and drink that suppresses the aroma caused by the flavonoid glycoside. .

本發明之課題係提供一種不藉由含有硫酸軟骨素之軟骨水系溶劑萃取物的抑制起因於槲黃素配糖體之香味的飲食物，及提供抑制來自槲黃素配糖體之香味的方法。 An object of the present invention is to provide a food or drink that does not inhibit the aroma derived from a flavonoid glycoside by a chondroitin aqueous solvent extract containing chondroitin sulfate, and a method for suppressing aroma derived from a flavonoid glycoside .

本發明人等為解決上述課題，再三深入研究探討時，發現藉由摻合咪唑胜肽，可有效地遮蔽槲黃素配糖體之苦味，遂而完成本發明。 In order to solve the above problems, the inventors of the present invention have further intensively studied and found that by blending an imidazole peptide, the bitterness of the flavonoid glycoside can be effectively shielded, and the present invention has been completed.

換言之，本發明包含下述之態樣，惟不受下述所限 制。 In other words, the present invention encompasses the following aspects, but is not limited to the following system.

(1)一種含有咪唑胜肽與槲黃素配糖體之組成物。 (1) A composition comprising an imidazole peptide and a quercetin glycoside.

(2)如(1)記載之組成物，其中槲黃素配糖體為酵素處理芸香素。 (2) The composition according to (1), wherein the flavin glycoside is an enzyme to treat the rutin.

(3)如(1)或(2)記載之組成物，其中進一步含有維生素D、蛋白多醣(proteoglycan)、葡糖胺類、硫酸軟骨素及膠原蛋白所成群中之至少1種。 (3) The composition according to (1) or (2), further comprising at least one of a group consisting of vitamin D, proteoglycan, glucosamine, chondroitin sulfate, and collagen.

(4)如(3)記載之組成物，其中膠原蛋白為II型膠原蛋白。 (4) The composition according to (3), wherein the collagen is type II collagen.

(5)如(1)至(4)中任一項記載之組成物，其中組成物為飲食物。 (5) The composition according to any one of (1) to (4) wherein the composition is a food or drink.

(6)如(5)記載之組成物，其中飲食物為固體製劑。 (6) The composition according to (5), wherein the food or drink is a solid preparation.

(7)如(6)記載之組成物，其中固體製劑為錠劑或顆粒劑。 (7) The composition according to (6), wherein the solid preparation is a tablet or granule.

(8)如(1)至(7)中任一項記載之組成物，其中咪唑胜肽與槲黃素配糖體之重量比為1：25~200：1。 (8) The composition according to any one of (1) to (7) wherein the weight ratio of the imidazole peptide to the quercetin glycoside is 1:25 to 200:1.

(9)如(5)至(8)中任一項記載之組成物，其係機能性食品。 (9) The composition according to any one of (5) to (8) which is a functional food.

(10)一種含有槲黃素配糖體之組成物的製造方法，其係包含在含槲黃素配糖體之組成物中摻合咪唑胜肽。 (10) A method for producing a composition comprising a quercetin glycoside, which comprises incorporating an imidazole peptide in a composition containing a flavin glycoside.

(11)一種含有槲黃素配糖體之組成物之香味改善方法，其特徵為摻合咪唑胜肽。 (11) A method for improving the flavor of a composition containing a flavonoid glycoside, characterized by blending an imidazole peptide.

本發明藉由在含槲黃素配糖體之組成物中摻合咪唑胜肽，可有效地抑制槲黃素配糖體特有的異味。而且，本發明之組成物由於可抑制起因於槲黃素配糖體之異味，故可容易持續攝取。 The present invention can effectively inhibit the peculiar odor of the flavonoid glycoside by blending the imidazole peptide in the composition containing the flavin glycoside. Further, since the composition of the present invention can suppress the odor caused by the flavonoid glycoside, it can be easily ingested continuously.

本發明係有關一種含有咪唑胜肽與槲黃素配糖體之組成物、含有槲黃素配糖體之組成物的製造方法、以及改善含有槲黃素配糖體之組成物異味的方法。 The present invention relates to a method for producing a composition comprising an imidazole peptide and a quercetin glycoside, a composition comprising a flavonoid glycoside, and a method for improving the odor of a composition containing a flavonoid glycoside.

於下述中，更詳細地說明有關本發明之實施形態。 Embodiments of the present invention will be described in more detail below.

<含有咪唑胜肽與槲黃素配糖體之組成物> <Composition containing an imidazole peptide and a quercetin glycoside>

本發明之組成物係含有咪唑胜肽與槲黃素配糖體。本發明之組成物可使用於包含獸醫藥用途之醫藥用途、包含補充劑之食品用途、化妝‧美容用途等。較佳者為飲食物，特別是於補充劑等食品用途中，要求日常可經口攝取時，本發明之組成物可有效地抑制槲黃素配糖體之香味，而為適合。 The composition of the present invention contains an imidazole peptide and a quercetin glycoside. The composition of the present invention can be used for medical applications including veterinary drug use, food use containing supplements, makeup, cosmetic use, and the like. Preferably, it is a food or drink, particularly in a food use such as a supplement, and it is required that the composition of the present invention can effectively suppress the flavor of the flavonoid glycoside when it is daily orally ingested.

i.咪唑胜肽 I. imidazole peptide

本發明之組成物含有咪唑胜肽。 The composition of the present invention contains an imidazole peptide.

咪唑胜肽係具有咪唑基之胺基酸結合體的總稱。此處，咪唑係在5環上之1,3位含有氮原子之含氮芳香雜環 式化合物之一。 The imidazole peptide is a generic term for an amino acid combination having an imidazole group. Here, the imidazole is a nitrogen-containing aromatic heterocyclic ring containing a nitrogen atom at the 1,3 position on the 5-ring. One of the compounds.

咪唑胜肽可有效地抑制槲黃素配糖體之異味。抑制異味之機構雖不明確，咪唑胜肽雖不為呈現香味遮蔽效果的成分，惟已知作為重口味賦予劑(日本特開平7-265008)，藉由該特性，咪唑胜肽具有可有效地抑制來自槲黃素配糖體之異味的可能性，但本發明不受下述推論所拘束。 The imidazole peptide can effectively inhibit the odor of the flavonoid glycoside. Although the mechanism for suppressing the odor is not clear, the imidazole peptide is not a component which exhibits a scent masking effect, but is known as a heavy flavor imparting agent (Japanese Patent Laid-Open No. Hei 7-265008), by which the imidazole peptide is effective. The possibility of odor from the quercetin glycoside is suppressed, but the present invention is not limited by the following inference.

咪唑胜肽由於亦廣泛地分布於人體中，特別是大多含於脊椎動物之肌肉中，故利用於以抑制肌力降低等之效果為目的的健康食品。如於本技術領域中所理解，本發明中之咪唑胜肽，係指包含肌肽(carosine)、甲肌肽(ancerine)、鯨肌肽(Balenine)、高絲胺酸(homoserine)等。咪唑胜肽含於肌肉中，特別是以高濃度含於必須具有持久力之飛鳥或鮪魚、柴魚等之迴游魚種中，作為肌肉之主成分時可達成其機能。另外，已報告隨著年齡增加，體內之咪唑胜肽亦隨著減少(Stuerenburg et al.,Arch.Gerontol.Geriatr.1999)，故體內一般代謝不足的部分必須以各種方法自體外補充。 Since the imidazole peptide is also widely distributed in the human body, and is particularly contained in the muscles of vertebrates, it is used for health foods for the purpose of suppressing the effects of muscle strength and the like. As understood in the art, the imidazole peptide in the present invention is meant to include carosine, ancerine, ballenine, homoserine, and the like. The imidazole peptide is contained in the muscle, and is particularly contained in a migratory fish species such as a bird or a squid or a squid that must have a long-lasting force, and can be achieved as a main component of the muscle. In addition, it has been reported that with the increase in age, the body's imidazole peptide is also reduced (Stuerenburg et al., Arch. Gerontol. Geriatr. 1999), so the generally metabolically depleted part of the body must be supplemented in vitro by various methods.

本發明之咪唑胜肽，如上所述包含肌肽、甲肌肽及鯨肌肽。肌肽係胜肽鍵結β-丙胺酸與L-組胺酸的二胜肽，甲肌肽係在肌肽之L-組胺酸殘基的1位上鍵結甲基者，鯨肌肽係具有在肌肽之L-組胺酸殘基之3位上鍵結甲基的構造。已知胜肽鍵結了γ-胺基丁酸(GABA)與L-組胺酸之高絲胺酸(homoserine)亦可作為咪唑胜肽。本發明 使用的咪唑胜肽可為此等中之任一者的咪唑胜肽。而且，於本發明中可僅使用上述各種咪唑胜肽之1種或組合複數種使用。 The imidazole peptide of the present invention comprises carnosine, myo-peptide and whale carnosine as described above. The carnosine is a peptide-bonded β-alanine and a dipeptide of L-histidine. The melanin peptide binds to the methyl group at the 1 position of the L-histamine residue of carnosine, and the whale carnosine has a carnosine. The structure of the methyl group bonded to the 3-position of the L-histamine residue. It is known that a peptide is bonded to gamma-aminobutyric acid (GABA) and L-histidine homologine can also be used as an imidazole peptide. this invention The imidazole peptide used can be an imidazole peptide of any of these. Further, in the present invention, only one type or a combination of the above various imidazole peptides may be used in combination.

本發明使用的咪唑胜肽，只要是自含有咪唑胜肽之材料(例如魚肉)以水系溶劑萃取而得者、或藉由化學合成而得者即可，其來源或原料沒有特別的限制。咪唑胜肽例如可得自鮪魚、柴魚、鮭魚、鳥等。一般而言，必須具有瞬發力之鳥等大多數具有肌肽的傾向，鮪魚、柴魚等必須具有持久力的動物大多數含有甲肌肽。於本發明中，可視所期望的效能或用途而定選擇咪唑胜肽之原料。 The imidazole peptide to be used in the present invention may be obtained by extracting a material (for example, fish meat) containing an imidazole peptide from an aqueous solvent or by chemical synthesis, and the source or raw material thereof is not particularly limited. The imidazole peptide can be obtained, for example, from salmon, campfish, salmon, birds, and the like. In general, it is necessary to have a tendency to have most of the carnosine, such as a bird of instant force, and most of the animals that must have endurance such as salmon or bonito contain melanin. In the present invention, the starting material of the imidazole peptide can be selected depending on the desired potency or use.

於本發明中，鮪魚、柴魚等迴游魚由於咪唑胜肽之含量高，以此等作為原料較佳。此等原料中所含的主要成分，係分子量240.26之甲肌肽及分子量226.24之鯨肌肽。此處，有關作為咪唑胜肽的原料之迴游魚種類，沒有特別的限制，且有關來源部位亦沒有特別限制。 In the present invention, migratory fish such as squid and bonito are preferred because of the high content of the imidazole peptide. The main components contained in these raw materials are melanin having a molecular weight of 240.26 and whale carnosine having a molecular weight of 226.24. Here, the type of migratory fish which is a raw material of the imidazole peptide is not particularly limited, and the source site is not particularly limited.

於本發明中，咪唑胜肽以使用水系溶劑萃取胜肽含有物較佳。水系溶劑萃取咪唑胜肽含有物，係指使用水系溶劑自原料萃取的咪唑胜肽含有物。除上述推論外，經由水萃取步驟之咪唑胜肽含有物與經單離的咪唑胜肽相比時，由於大多數另含有麩胺酸鈉等之甘味成分，故推測可更為有效地抑制起因於槲黃素配糖體之異味。 In the present invention, the imidazole peptide is preferably extracted by using an aqueous solvent to extract a peptide. The aqueous solvent extracts the imidazole peptide-containing substance, and refers to the imidazole peptide-containing material extracted from the raw material using an aqueous solvent. In addition to the above inference, when the imidazole peptide content in the water extraction step is compared with the isolated imidazole peptide, since most of the other contains a sweet component such as sodium glutamate, it is presumed that the cause can be more effectively suppressed. The odor of the flavonoids in the flavonoids.

於上述中，以使用水作為水系溶劑較佳。水可列舉例如各種溫度的水(熱水、溫水、常溫水)。例如，咪唑胜肽含有物係可自鮪魚、柴魚等之煮汁分離油份，且藉由脫 色˙脫臭˙脫鹽˙濃縮等之方法精製，加入糊精等之賦形劑，以噴霧乾燥等方法形成粉末狀而得。 Among the above, it is preferred to use water as the aqueous solvent. Examples of the water include water of various temperatures (hot water, warm water, and room temperature water). For example, the imidazole peptide-containing system can separate oil from the cooking juice of squid, bonito, etc., and Color ̇ deodorization ̇ Desalting ̇ Concentration and other methods are refined, and an excipient such as dextrin is added thereto to form a powder by spray drying or the like.

於本發明中，不僅使用水系溶劑萃取咪唑胜肽含有物，亦可使用化學合成咪唑胜肽、及除去蛋白質之咪唑胜肽(蛋白質除去品)作為咪唑胜肽。市售品例如作為水系溶劑萃取咪唑胜肽含有物之MARINE ACTIVE 10(燒津水產化學製)，作為化學合成咪唑胜肽之PROMAC(Zeria新藥製)等。 In the present invention, not only the aqueous solvent is used for extracting the imidazole peptide, but also the imidazole peptide and the protein-removing imidazole peptide (protein-removed product) can be used as the imidazole peptide. Commercially available product, for example, MARINE ACTIVE 10 (manufactured by Yaizu Aquarium Chemical Co., Ltd.), which is an aqueous solution of an imidazole peptide, is used as a chemically synthesized imidazole peptide, PROMAC (manufactured by Zeria New Drug Co., Ltd.).

使用本發明之組成物作為飲食品時，可決定咪唑胜肽之摻合量在每一個體中咪唑胜肽以1日1~1500mg較佳，更佳者為2.5~100mg作為標準。此外，每1kg體重之攝取量，例如可為0.02~30.0mg/kg，較佳者為0.05~2.00mg/kg。另外，咪唑胜肽對飲食物的摻合比例，相對於組成物全體而言咪唑胜肽以0.01~95.0重量%較佳，更佳者為0.05~1.0重量%，特佳者為0.1~0.5重量%。 When the composition of the present invention is used as a food or drink, the blending amount of the imidazole peptide can be determined. In each individual, the imidazole peptide is preferably 1 to 1500 mg per day, more preferably 2.5 to 100 mg. Further, the intake per 1 kg of body weight may be, for example, 0.02 to 30.0 mg/kg, preferably 0.05 to 2.00 mg/kg. Further, the blending ratio of the imidazole peptide to the food or drink is preferably 0.01 to 95.0% by weight, more preferably 0.05 to 1.0% by weight, and particularly preferably 0.1 to 0.5% by weight based on the entire composition. %.

ii.槲黃素配糖體 Ii. flavonoid glycoside

本發明之組成物中含有槲黃素配糖體。 The composition of the present invention contains a flavonoid glycoside.

下述之槲黃素配糖體具有抗發炎的作用，推測藉由同時攝取硫酸軟骨素，可更為有效地減低關節痛等之疼痛。於本發明中，槲黃素配糖體係呋喃型化合物之一種的槲黃素(亦稱為quercetin)之配糖體，例如芸香素、槲皮苷、異槲皮苦、桑色素、楊梅苷、楊梅黃酮、橘皮苷、柚苷、紅橘黃酮等，亦包含此處之槲黃素配糖體之酵素處理物。 The following flavin glycoside has an anti-inflammatory action, and it is presumed that by simultaneously taking chondroitin sulfate, pain such as joint pain can be more effectively reduced. In the present invention, a flavonoid (also known as quercetin) glycoside of a flavonoid compound of the quercetin glycoside system, such as rutin, quercetin, quercetin, morin, and myricetin, Bayberry flavonoids, hesperidin, naringin, red tangerine flavonoids, etc., also contain the enzyme treatment of the flavonoid glycoside herein.

已知槲黃素配糖體具有各種生理作用，報告有抗發炎作用、抗氧化作用、血管收縮作用、抑制透過毛細血管之作用、增強毛細血管壁之效果以及阻礙有關細胞增殖等之各種酵素。然而，槲黃素配糖體具有獨特的香味(特別是苦味)，不易作為食品於日常經口攝取。 It is known that quercetin glycoside has various physiological effects, and has been reported to have anti-inflammatory effects, anti-oxidation effects, vasoconstriction effects, inhibition of action through capillaries, enhancement of capillary wall effects, and various enzymes which hinder cell proliferation. However, the quercetin glycoside has a unique aroma (especially bitterness) and is not easily taken as a food for daily oral intake.

本發明之組成物的槲黃素配糖體，以芸香素或其類似物較佳。芸香素類係呋喃型化合物之一種，由於具有如維生素的作用，故作為類維生素物質。一般而言，不受限於橘科之植物，亦可自豆科之槐樹或蓼科之蕎麥類等而得。 The quercetin glycoside of the composition of the present invention is preferably rutin or the like. A kind of a furan-type compound of a ruthenium-based compound is a vitamin-like substance because it has a vitamin-like action. In general, it is not limited to plants of the family Orange, but may also be obtained from the eucalyptus or the buckwheat of the family.

本發明使用的槲黃素配糖體，有關其來源、製法沒有特別的限制。例如含有大量槲黃素的植物，已知有刺山柑、蘋果、茶、洋蔥、葡萄、花椰菜、山麻、覆盆子、濱梨、蔓越莓、仙人掌類、菜葉類、柑橘類等，可自此等植物得到槲黃素配糖體。 The flavonoid glycoside used in the present invention is not particularly limited in terms of its source and preparation method. For example, plants containing a large amount of quercetin, known as capers, apples, tea, onions, grapes, broccoli, sage, raspberries, pears, cranberries, cactus, leaves, citrus, etc. From these plants, the flavonoid glycoside is obtained.

於本發明之較佳形態中，可使用以糖轉移酵素等處理槲黃素配糖體予以糖轉移者作為槲黃素配糖體。雖然芸香素等之槲黃素配糖體難溶於水中故而會有不易使用的情形，但因槲黃素配糖體之酵素處理物會因為糖轉移而提高水溶性，故可使用於本發明之組成物。 In a preferred embodiment of the present invention, a flavonoid glycoside can be used as a flavonoid glycoside by treating a flavonoid glycoside with a glycosyltransferase or the like. Although the flavonoid glycoside such as ruthenium is hardly soluble in water, it may be difficult to use, but since the enzyme treatment of the flavonoid glycoside may increase water solubility due to sugar transfer, it can be used in the present invention. Composition.

於本發明之特佳的形態中，槲黃素配糖體係使用芸香素之酵素處理物(以下稱為酵素處理芸香素)。酵素處理芸香素亦稱為酵素處理異槲皮苷或糖轉移芸香素，以使芸香素及其類似物進行酵素處理而糖轉移的α-糠基異槲皮苷為主成分者。一般而言，雖已知芸香素具有抗氧化作用， 惟由於對水而言為難溶性，故於使用用途受到限制，酵素處理芸香素可藉由進行糖轉移而提高水溶性。酵素處理芸香素，除具有強力的抗氧化活性外，已知具有抑制血小板之凝聚作用及抑制黏接作用、血管擴張作用、抗癌作用等之各種生理機能，利用於以改善發炎狀或促進血液循環等效果為目的之健康食品。有關酵素處理芸香素，例如可以糖轉移酵素處理槐樹、蕎麥等之萃取物而得。例如可以日本特開平7-10898號記載的方法製得。 In a particularly preferred embodiment of the present invention, the quercetin glycoside system uses an enzyme treatment of rutin (hereinafter referred to as an enzyme treatment of rutin). Enzyme treatment of rutin is also known as enzyme treatment of isoquercitrin or sugar transfer of rutin, in order to make rutin and its analogues are enzymatically treated with sugar-transfered α-mercaptoisoquercitrin as the main component. In general, although it is known that rutin has an antioxidant effect, However, since it is insoluble in water, it is limited in its use, and the enzyme-treated musk can improve water solubility by performing sugar transfer. In addition to its powerful antioxidant activity, enzymes are known to have various physiological functions such as inhibiting aggregation of platelets and inhibiting adhesion, vasodilatation, and anticancer effects, and are used to improve inflammation or promote blood. Healthy food for the purpose of circulation and other effects. The enzyme-treated rutin, for example, can be obtained by treating an extract of eucalyptus or buckwheat with a sugar transferase. For example, it can be obtained by the method described in JP-A-7-10898.

槲黃素配糖體在本發明組成物中之摻合量，大致上可決定於每一個體中酵素處理芸香素之攝取量為1日1~500mg(較佳者5~300mg)。而且，每1kg體重之攝取量，例如0.02~10mg/kg、較佳者0.10~6.0mg/kg。此外，槲黃素配糖體對飲食物之摻合比例，相對於組成物全體而言為0.1~95重量%、較佳者0.5~80重量%、更佳者1.0~10重量%。 The blending amount of the flavonoid glycoside in the composition of the present invention can be roughly determined by the intake of the enzyme-treated musk saponin in each individual from 1 to 500 mg (preferably from 5 to 300 mg) per day. Further, the intake per 1 kg of body weight is, for example, 0.02 to 10 mg/kg, preferably 0.10 to 6.0 mg/kg. Further, the blending ratio of the flavonoid glycoside to the food or drink is 0.1 to 95% by weight, preferably 0.5 to 80% by weight, and more preferably 1.0 to 10% by weight based on the entire composition.

於本發明之組成物中，咪唑胜肽與槲黃素配糖體之重量比為1：25~200：1，較佳者為1：20~50：1。 In the composition of the present invention, the weight ratio of the imidazole peptide to the flavonoid glycoside is 1:25 to 200:1, preferably 1:20 to 50:1.

iii.維生素D Iii. Vitamin D

於較佳的形態中，本發明組成物中進一步含有維生素D。 In a preferred embodiment, the composition of the invention further comprises vitamin D.

作為因年齡增加而肌力降低的對策中攝取維生素D的方法，係探討安全性高的處理法(Food style 21 14(12)40-42(2010))。此外，維生素D被報告會抑制肌肉分 解(John J.Cannell,et al.,Medicine & Science in Sports & Exercise,p1102-1110,2009)，將維生素D與咪唑胜肽一起摻合於本發明之組成物中較佳。 As a method of taking vitamin D in response to a decrease in muscle strength due to an increase in age, a highly safe treatment method (Food style 21 14(12) 40-42 (2010)) is proposed. In addition, vitamin D is reported to inhibit muscle mass It is preferred to incorporate vitamin D with the imidazole peptide in the composition of the present invention (John J. Cannell, et al., Medicine & Science in Sports & Exercise, p1102-1110, 2009).

近年來，維生素D不僅確認作為活體成分之基本構成分子之重要性，且視其攝取而確認有各種有效性。自古已知有提高腸道之鈣的吸收效率，另外亦已知對肌肉或神經具有有效作用。於本發明之組成物中，如上所述，除了咪唑胜肽及槲黃素配糖體外，以摻合可期待抑制肌力降低的可能性之維生素D較佳。 In recent years, vitamin D has not only confirmed the importance of being a basic constituent molecule of a living component, but has confirmed various effects depending on its intake. It has been known since ancient times to increase the absorption efficiency of calcium in the intestine, and it is also known to have an effective effect on muscles or nerves. In the composition of the present invention, as described above, in addition to the imidazole peptide and the quercetin glycoside, it is preferred to blend vitamin D which is expected to inhibit the decrease in muscle strength.

維生素D係有植物產生的維生素D2與動物產生的維生素D3。已知對人體而言有效者為維生素D3，工業上可藉由自羊毛脂分離、精製而得。 Vitamin D is a vitamin D 2 produced by plants and vitamin D 3 produced by animals. It is known that it is effective for human body to be vitamin D 3 , and it can be industrially obtained by separating and refining from lanolin.

另外，亦可含有食品或醫藥品中一般使用的添加劑或輔助成分，例如亦可含有甜味料、酸味料、賦形劑、潤滑劑、香味料、澱粉、糊精等。此外，有關維生素D2、維生素D3之種類，亦沒有特別的限制，於本發明中簡稱為維生素D時，亦包含維生素D2、維生素D3。 Further, it may contain additives or auxiliary ingredients which are generally used in foods or pharmaceuticals, and may contain, for example, sweeteners, sour materials, excipients, lubricants, flavorings, starches, dextrin, and the like. Further, the types of vitamin D 2 and vitamin D 3 are not particularly limited, and in the case of the present invention, simply referred to as vitamin D, vitamin D 2 and vitamin D 3 are also included.

維生素D在本發明組成物中之摻合量，維生素D之攝取量可決定每一個體中1日0.5~50μg、較佳者1~25μg作為標準。此外，每1kg體重之攝取量，例如可為0.01~1μg/kg、較佳者0.02~0.5μg/kg。例如，維生素D對飲食品之摻合比例，相對於組成物全體而言為0.00001~95重量%、較佳者為0.00005~10重量%、更佳者為0.0001~0.001重量%。 The amount of vitamin D blended in the composition of the present invention, the intake of vitamin D can be determined as 0.5 to 50 μg, preferably 1 to 25 μg per day in each individual as a standard. Further, the intake per 1 kg of body weight may be, for example, 0.01 to 1 μg/kg, preferably 0.02 to 0.5 μg/kg. For example, the blending ratio of vitamin D to food or drink is 0.00001 to 95% by weight, preferably 0.00005 to 10% by weight, and more preferably 0.0001 to 0.001% by weight based on the total amount of the composition.

iv.其他成分 Iv. Other ingredients

本發明之組成物，除咪唑胜肽及槲黃素配糖體外，亦可含有其他的具有活體內機能性之原料(例如蛋白多醣、葡糖胺類、硫酸軟骨素、II型膠原蛋白等之膠原蛋白、透明質酸、維生素等)。 The composition of the present invention may contain other in vivo functional materials (for example, proteoglycan, glucosamine, chondroitin sulfate, type II collagen, etc.) in addition to the imidazole peptide and the quercetin glycoside. Collagen, hyaluronic acid, vitamins, etc.).

本發明之組成物，除咪唑胜肽及槲黃素配糖體外，以含有蛋白多醣較佳。蛋白多醣係共價鍵結有蛋白質與糖鏈(葡糖胺多醣)之複合糖質的一種，併有膠原蛋白或透明質酸之動物軟骨的主成分。蛋白多醣係保水性優異、可經口攝取、對人體而言安全的物質。而且，蛋白多醣係作成膠原蛋白或透明質酸與細胞外基體，維持身體組織之成分，暗示對軟骨而言之有效性(Sashinami,et al.BBRC 2006)。 The composition of the present invention preferably contains a proteoglycan in addition to the imidazole peptide and the quercetin glycoside. The proteoglycan is covalently bonded to a complex carbohydrate of a protein and a sugar chain (glucosamine polysaccharide), and has a main component of collagen or hyaluronic acid animal cartilage. Proteoglycans are substances that are excellent in water retention, can be taken orally, and are safe for the human body. Moreover, proteoglycans act as collagen or hyaluronic acid and extracellular matrix, maintaining the composition of body tissues, suggesting effectiveness for cartilage (Sashinami, et al. BBRC 2006).

蛋白多醣在本發明組成物中之摻合量，可決定蛋白多醣之攝取量在每一個體中1日為0.1~1000mg，較佳者為1~50mg作為標準。此外，每1kg體重之攝取量，例如0.002~20mg/kg，較佳者為0.02~1.0mg/kg。例如蛋白多醣對飲食物之摻合比例，相對於組成物全體而言較佳者為0.001~95重量%、更佳者為0.01~10.0重量%、最佳者為0.02~1.0重量%。 The amount of proteoglycan incorporated in the composition of the present invention determines that the amount of proteoglycan uptake is from 0.1 to 1000 mg, preferably from 1 to 50 mg, per day in each individual as a standard. Further, the intake per 1 kg of body weight is, for example, 0.002 to 20 mg/kg, preferably 0.02 to 1.0 mg/kg. For example, the blending ratio of the proteoglycan to the food or drink is preferably 0.001 to 95% by weight, more preferably 0.01 to 10.0% by weight, and most preferably 0.02 to 1.0% by weight based on the total amount of the composition.

於較佳的形態中，本發明之製劑含有葡糖胺。葡糖胺係葡萄糖之2位羥基被胺基取代的2-胺基葡萄糖，在自然界中廣泛分布於天然胺基糖作為活體成分之糖蛋白質、糖 脂質、黏多醣等之構成糖分子。近年來，葡糖胺不僅確認具有作為活體成分之基本構成分子的重要性，且可確認藉由攝取而具有各種有效性，被廣泛地利用於以治療‧預防關節痛或變形性關節症狀等之效果為目的的健康食品，於本發明之製劑中亦以同時摻合咪唑胜肽或槲黃素配糖體為宜。 In a preferred form, the formulation of the invention contains glucosamine. Glucosamine-based 2-aminoglycol, in which the hydroxyl group at the 2-position of the hydroxyl group is substituted with an amine group, is widely distributed in nature as a glycoprotein, sugar which is a living component of natural amino sugar. A lipid molecule such as a lipid or a mucopolysaccharide. In recent years, glucosamine has not only confirmed the importance of having a basic constituent molecule as a living component, but also has various effects by ingestion, and is widely used for the treatment of ‧ prevention of joint pain or deformed joint symptoms For the purpose of the health food for the purpose, it is preferred to simultaneously incorporate the imidazole peptide or the quercetin glycoside in the preparation of the present invention.

葡糖胺在本發明組成物中之摻合量，大致上可決定每一個體中葡糖胺之攝取量為100~5000mg、較佳者為300~2000mg作為標準。而且，每1kg體重之攝取量，例如可為2~100mg/kg、較佳者為6.0~40.0mg/kg。例如葡糖胺在錠劑中之摻合比例，相對於錠劑全體而言為0.1~95重量%、較佳者為10~80重量%。 The blending amount of glucosamine in the composition of the present invention can substantially determine the amount of glucosamine intake in each individual of 100 to 5000 mg, preferably 300 to 2000 mg as a standard. Further, the intake per 1 kg of body weight may be, for example, 2 to 100 mg/kg, preferably 6.0 to 40.0 mg/kg. For example, the blending ratio of glucosamine in the tablet is 0.1 to 95% by weight, preferably 10 to 80% by weight based on the entire tablet.

此外，於較佳的形態中，本發明之製劑含有硫酸軟骨素。硫酸軟骨素亦廣泛地分布於人體中，特別是由於大多數含於關節部之軟骨或皮膚中，故可利用於以改善變形性關節症狀或美容皮膚等之效果為目的的醫藥品或健康食品。於本發明之組成物中，硫酸軟骨素亦可包含其鹽。 Further, in a preferred embodiment, the preparation of the present invention contains chondroitin sulfate. Chondroitin sulfate is also widely distributed in the human body, and in particular, it is used in cartilage or skin of the joint portion, so that it can be used for medicines or health foods for the purpose of improving the effects of deformed joint symptoms or cosmetic skin. . In the composition of the present invention, chondroitin sulfate may also contain a salt thereof.

硫酸軟骨素之摻合量，可決定硫酸軟骨素之攝取量在每一個體中為1日10~3000mg、較佳者為50~1000mg作為標準。而且，每1kg體重之攝取量，例如可為0.2~60.0mg/kg、較佳者為1.0~20.0mg/kg。另外，硫酸軟骨素在經口製劑中之摻合比例，相對於製劑全體而言為0.1~95重量%較佳，更佳者為0.5~20重量%。 The amount of chondroitin sulfate blended may determine the amount of chondroitin sulfate uptake in each individual from 10 to 3000 mg per day, preferably from 50 to 1000 mg. Further, the intake per 1 kg of body weight may be, for example, 0.2 to 60.0 mg/kg, preferably 1.0 to 20.0 mg/kg. Further, the blending ratio of chondroitin sulfate in the oral preparation is preferably from 0.1 to 95% by weight, more preferably from 0.5 to 20% by weight, based on the entire preparation.

另外，本發明之組成物除咪唑胜肽及槲黃素配糖體 外，以含有膠原蛋白較佳。膠原蛋白係構成真皮、韌帶、肌腱、骨、軟骨等之蛋白質之一，為多細胞動物之細胞外基質(細胞外基體)的主成分。膠原蛋白中之II型膠原蛋白，係蛋白多醣或水與關節內軟骨之構成成分而。II型膠原蛋白等之膠原蛋白在本發明組成物中之摻合量，大致上在每一個體中攝取量為1日0.1~1000mg、較佳者1~100mg。此外，每1kg體重之攝取量，例如可為0.002~20mg/kg、較佳者為0.02~2.0mg/kg。例如膠原蛋白在飲食物中之摻合比例，相對於組成物全體而言較佳者為0.001~95重量%、更佳者為0.01~10.0重量%、最佳者為0.02~5.0重量%。於本發明之組成物中摻合膠原蛋白時，亦可為膠原蛋白胜肽。此外，亦可摻合含有一定量的硫酸軟骨素或膠原蛋白之已知的鯊魚或鮭魚等魚類的軟骨水萃取物。 In addition, the composition of the present invention contains, in addition to the imidazole peptide and the quercetin glycoside In addition, it is preferred to contain collagen. Collagen is one of the proteins of the dermis, ligament, tendon, bone, cartilage, etc., and is the main component of the extracellular matrix (extracellular matrix) of multicellular animals. Collagen type II collagen, which is a component of proteoglycan or water and intra-articular cartilage. The amount of collagen of type II collagen or the like in the composition of the present invention is substantially 0.1 to 1000 mg per day, preferably 1 to 100 mg, per one body. Further, the intake per 1 kg of body weight may be, for example, 0.002 to 20 mg/kg, preferably 0.02 to 2.0 mg/kg. For example, the blending ratio of collagen in the food and beverage is preferably 0.001 to 95% by weight, more preferably 0.01 to 10.0% by weight, and most preferably 0.02 to 5.0% by weight based on the total amount of the composition. When collagen is incorporated into the composition of the present invention, it may also be a collagen peptide. Further, a cartilage water extract of a fish such as a known shark or squid containing a certain amount of chondroitin sulfate or collagen may be blended.

而且，於本發明之製劑中，亦可進一步摻合透明質酸。透明質酸係以鍵結N-乙醯基葡糖胺與葡糖醛酸之二糖單位的構造作為基礎單位之聚合物。分子量係廣泛分布於自約數萬的低分子量者至200萬以上之高分子量者，於本發明中以使用分子量10萬~300萬之透明質酸較佳。 Further, in the preparation of the present invention, hyaluronic acid may be further blended. Hyaluronic acid is a polymer which is a basic unit of a structure in which a N-acetyl glucosamine and a glucuronic acid disaccharide unit are bonded. The molecular weight is widely distributed from a low molecular weight of about tens of thousands to a high molecular weight of 2,000,000 or more. In the present invention, hyaluronic acid having a molecular weight of 100,000 to 3,000,000 is preferably used.

透明質酸係在活體內關節、水晶體、皮膚、腦等之廣布活體內的細胞外基體成分，特別是對於維持軟骨之機能而言為重要的角色。 Hyaluronic acid is an extracellular matrix component that is widely distributed in vivo, such as joints, crystals, skin, and brain in vivo, and is particularly important for maintaining the function of cartilage.

透明質酸之摻合量，可決定每一個體中透明質酸之攝取量為1日1~3000mg為宜，較佳者為15~1000mg作為 標準。另外，每1kg體重之攝取量，例如可為0.02~60.0mg/kg、較佳者為0.3~20.0mg/kg。此外，透明質酸在經口製劑中之摻合比例，相對於製劑全體而言以0.1~95重量%較佳，更佳者為0.5~20重量%。 The amount of hyaluronic acid blended may determine that the intake of hyaluronic acid in each individual is preferably from 1 to 3000 mg per day, preferably from 15 to 1000 mg. standard. Further, the intake per 1 kg of body weight may be, for example, 0.02 to 60.0 mg/kg, preferably 0.3 to 20.0 mg/kg. Further, the blending ratio of hyaluronic acid in the oral preparation is preferably from 0.1 to 95% by weight, more preferably from 0.5 to 20% by weight based on the total amount of the preparation.

另外，於本發明之製劑中，亦可摻合除上述維生素D外之其他維生素類。 Further, in the preparation of the present invention, other vitamins other than the above vitamin D may be blended.

此外，亦可含有食品或醫藥品中一般使用的添加劑或輔助成分，例如甜味料、酸味料、賦形劑、潤滑劑、香味料、澱粉、糊精等。 Further, it may contain additives or auxiliary ingredients generally used in foods or pharmaceuticals, such as sweeteners, sour materials, excipients, lubricants, flavors, starches, dextrin, and the like.

v.組成物 Composition

本發明之組成物，可使用作為食品、醫藥品、化妝品、食品用添加物。本發明之組成物，由於可抑制起因於槲黃素配糖體之苦味，故於日常中可輕易攝取而適合作為所謂機能性食品等之食品來使用。 The composition of the present invention can be used as an additive for foods, pharmaceuticals, cosmetics, and foods. Since the composition of the present invention can suppress the bitter taste caused by the flavonoid glycoside, it can be easily taken in daily life and is suitably used as a food such as a so-called functional food.

作為飲食物之組成物，由於可藉由咪唑胜肽來抑制起因於槲黃素配糖體的異味，以適合經口投予的形態較佳，例如錠劑、膠囊、顆粒劑、粉末、或錠劑等之形態。其中，本發明之飲食物，由於含有異味成分之槲黃素配糖體，以錠劑或顆粒劑較佳。而且，由於亦可使用水系溶劑萃取咪唑胜肽含有物作為咪唑胜肽，亦以液劑較佳。 As a constituent of the food and drink, since the odor of the quercetin glycoside can be inhibited by the imidazole peptide, it is preferably in a form suitable for oral administration, such as a tablet, a capsule, a granule, a powder, or The form of tablets and the like. Among them, in the food or drink of the present invention, a flavonoid glycoside containing an odor component is preferred, and a tablet or granule is preferred. Further, since the imidazole peptide-containing substance can also be extracted as an imidazole peptide using an aqueous solvent, it is also preferable to use a liquid agent.

本發明之組成物的較佳形態，可調製為每1錠劑之重量為50mg~5000mg，較佳者為70mg~1000mg之錠劑。而且，若為顆粒劑，可調製成每1包之重量為50mg~ 5000mg、較佳者300mg~3000mg之分包的顆粒劑，此外，為瓶裝等之容器包裝時，每1容器例如可調製成5g~5kg之顆粒劑。而且，為飲料用劑等之液劑時，例如可調製成5g~2kg之裝入容器製品。 A preferred embodiment of the composition of the present invention can be prepared as a tablet having a weight of 50 mg to 5000 mg, preferably 70 mg to 1000 mg per tablet. Moreover, if it is a granule, it can be adjusted to make a weight of 50mg per 1 pack~ The granules of 5000 mg, preferably 300 mg to 3000 mg, in addition, when packaged in a container such as a bottle, can be made into a granule of 5 g to 5 kg per container, for example. Further, in the case of a liquid preparation such as a beverage, for example, it can be adjusted to be a container product of 5 g to 2 kg.

本發明之組成物的攝取對象，沒有特別的限制，可為人體，亦可為人體以外之動物。可視投予對象而定適當選擇組成物之劑形，例如以人體為對象時，由於被確認肌力降低的中高年齡層無法吞嚥錠劑時，製劑以顆粒劑、可咀嚼錠劑較佳。而且，於本發明之製劑中亦可施予糖衣、薄膜塗覆等之塗覆處理。另外，除人體外之動物中，由於適口性對投予容易性有很大的影響，本發明之製劑適合投予動物。例如，對具有於口中咀嚼錠劑傾向之寵物(特別是狗或貓)而言，以選擇可咀嚼錠劑作為劑形較佳。 The object to be ingested by the composition of the present invention is not particularly limited, and may be a human body or an animal other than a human body. The dosage form of the composition may be appropriately selected depending on the subject to be administered. For example, when the middle and high age layers in which the muscle strength is reduced cannot be swallowed, the preparation is preferably a granule or a chewable tablet. Further, a coating treatment such as sugar coating, film coating or the like may be applied to the preparation of the present invention. Further, in the animal other than human, since the palatability has a great influence on the easiness of administration, the preparation of the present invention is suitable for administration to an animal. For example, for a pet (especially a dog or a cat) having a tendency to chew a lozenge in the mouth, it is preferred to select a chewable tablet as a dosage form.

<含有槲黃素配糖體之組成物的製造方法> <Method for Producing Composition Containing Quercetin Glycoside>

就另一觀點而言，本發明係包含在含槲黃素配糖體之組成物中摻合咪唑胜肽之含槲黃素配糖體的組成物之製造方法。該方法係包含在含槲黃素配糖體之組成物中摻合咪唑胜肽的步驟。 In another aspect, the present invention is a process for producing a composition comprising a flavonoid glycoside containing an imidazole peptide in a composition comprising a flavin glycoside. The method comprises the step of incorporating an imidazole peptide in a composition comprising a flavin glycoside.

有關槲黃素配糖體、咪唑胜肽等，參照上述<含咪唑胜肽與槲黃素配糖體之組成物>中之說明。 Regarding the flavonol glycoside, the imidazole peptide, and the like, reference is made to the above description of the composition of the imidazole-containing peptide and the flavonoid glycoside.

<改善含槲黃素配糖體之組成物之味道的方法> <Method for improving the taste of a composition containing a flavonoid glycoside>

就另一觀點而言，可了解本發明係以摻合咪唑胜肽為 特徵之含槲黃素配糖體之飲食物的香味改善方法。該方法由包含摻合咪唑胜肽而成。 From another point of view, it can be understood that the present invention is based on the incorporation of imidazole peptides. A method for improving the flavor of a food or drink containing a flavonoid glycoside. The method consists of comprising a blend of imidazole peptides.

同樣地，有關槲黃素配糖體、咪唑胜肽等，參照上述<含咪唑胜肽與槲黃素配糖體之組成物>中之說明。 Similarly, regarding the flavonoid glycoside, the imidazole peptide, and the like, reference is made to the above description of the composition of the imidazole-containing peptide and the flavonoid glycoside.

〔實施例〕 [Examples]

於下述中，以實施例為基準說明本發明，惟本發明不受此等實施例所限制。而且，沒有特別的限制時，本說明書中記載的份及%等係以重量為基準，數值範圍包含其端點。 In the following, the invention is illustrated on the basis of the examples, but the invention is not limited by the examples. Further, in the case where there is no particular limitation, the parts and % described in the present specification are based on the weight, and the numerical range includes the end points thereof.

實施例1 Example 1

於含有槲黃素配糖體之組成物中，探討適合遮蔽槲黃素配糖體之異味的方法。具體而言，係作為用以遮蔽槲黃素配糖體之異味時的成分，來試驗咪唑胜肽、糊精。 In the composition containing the flavonoid glycoside, a method suitable for masking the odor of the flavonoid glycoside is discussed. Specifically, the imidazole peptide and dextrin were tested as components for masking the odor of the flavonoid glycoside.

(材料) (material)

使用的材料如下所述。 The materials used are as follows.

(1)槲黃素配糖體：San’emikku P15(三榮源F‧F‧I製、含槲黃素配糖體15%) (1) quercetin glycoside: San’emikku P15 (Sanrongyuan F‧F‧I, containing quercetin glycoside 15%)

(2)咪唑胜肽：Anserine(生化學Biobusiness製、含甲肌肽95%) (2) Imidazole peptide: Anserine (manufactured by Biochemistry, containing carnosine 95%)

(3)糊精：PINEDEX#100(松谷化學製) (3) Dextrin: PINEDEX #100 (made by Matsutani Chemical Co., Ltd.)

(評估方法) (evaluation method)

使用含有上述槲黃素配糖體或各種遮蔽成分之材料，調製以各成分之混合比例如表1所示之組成的方式摻合的混合粉末。使6名試驗人員經口攝取所調製的混合粉末1g與水，且以下述基準進行評估起因於槲黃素配糖體之苦味強度。 A mixed powder blended in such a manner that the mixing ratio of each component is as shown in Table 1 is prepared using a material containing the above-described flavin glycoside or various masking components. Six testers were orally ingested 1 g of the prepared mixed powder and water, and the bitterness intensity due to the quercetin glycoside was evaluated on the basis of the following criteria.

以僅槲黃素配糖體之苦味強度為1分，以1~5分進行評估。 The bitterness intensity of only the quercetin glycoside was 1 point, and it was evaluated by 1 to 5 points.

1分：「感覺與槲黃素配糖體同等強烈的苦味」 1 point: "I feel the same bitter taste as the flavonoid glycoside"

2分：「感覺弱的苦味」 2 points: "Feel weak bitterness"

3分：「感覺稍弱的苦味」 3 points: "I feel a bit weaker bitterness"

4分：「幾乎感覺不到苦味」 4 points: "I can hardly feel bitterness."

5分：「完全沒有感覺到苦味」 5 points: "I don't feel bitter at all."

集計6名試驗人員之評估，分數之平均值未達1.5時為×，1.5分以上、未達2.5分時為△，2.5分以上為○。結果如表1所示。 The evaluation of six testers was performed. When the average value of the scores was less than 1.5, it was ×, 1.5 points or more, when it was less than 2.5 points, it was △, and when it was 2.5 points or more, it was ○. The results are shown in Table 1.

由表1之結果可知，藉由摻合咪唑胜肽，可有效地遮 蔽槲黃素配糖體之苦味。 From the results of Table 1, it can be seen that by blending the imidazole peptide, it can effectively cover The bitter taste of the flavonoids.

實施例2 Example 2

於含槲黃素配糖體之組成物中，進行探討適合遮蔽槲黃素配糖體之異味的摻合比例。具體而言，為遮蔽槲黃素配糖體之異味時的成分，係使用咪唑胜肽及糊精，進行探討其摻合比例。 In the composition containing the flavonoid glycoside, the blending ratio suitable for masking the odor of the flavonoid glycoside is investigated. Specifically, in order to mask the odor of the flavonoid glycoside, the imidazole peptide and dextrin are used, and the blending ratio thereof is examined.

(材料) (material)

使用的材料如下所述。 The materials used are as follows.

(1)槲黃素配糖體：San’emikku P15(三榮源F‧F‧I製、含槲黃素配糖體15%) (1) quercetin glycoside: San’emikku P15 (Sanrongyuan F‧F‧I, containing quercetin glycoside 15%)

(2)咪唑胜肽：Anserine(生化學Biobusiness製、含甲肌肽95%) (2) Imidazole peptide: Anserine (manufactured by Biochemistry, containing carnosine 95%)

(評估方法) (evaluation method)

使用含有上述槲黃素配糖體或各種遮蔽成分之材料，調製以各成分之混合比例如表2所示之組成的方式摻合的混合粉末。使6名試驗人員經口攝取所調製的混合粉末1g與水，且以下述基準進行評估起因於槲黃素配糖體之苦味強度。 A mixed powder blended in such a manner that the mixing ratio of each component is as shown in Table 2 is prepared using a material containing the above-described flavin glycoside or various masking components. Six testers were orally ingested 1 g of the prepared mixed powder and water, and the bitterness intensity due to the quercetin glycoside was evaluated on the basis of the following criteria.

以僅槲黃素配糖體之苦味強度為1分，以1~5分進行評估。 The bitterness intensity of only the quercetin glycoside was 1 point, and it was evaluated by 1 to 5 points.

1分：「感覺與槲黃素配糖體同等強烈的苦味」 1 point: "I feel the same bitter taste as the flavonoid glycoside"

2分：「感覺弱的苦味」 2 points: "Feel weak bitterness"

3分：「感覺稍弱的苦味」 3 points: "I feel a bit weaker bitterness"

4分：「幾乎感覺不到苦味」 4 points: "I can hardly feel bitterness."

5分：「完全沒有感覺到苦味」 5 points: "I don't feel bitter at all."

集計6名試驗人員之評估，分數之平均值未達1.5時為×，1.5分以上、未達2.5分時為△，2.5分以上為○。結果如表2所示。 The evaluation of six testers was performed. When the average value of the scores was less than 1.5, it was ×, 1.5 points or more, when it was less than 2.5 points, it was △, and when it was 2.5 points or more, it was ○. The results are shown in Table 2.

由表2之結果可知，藉由摻合一定量以上之咪唑胜肽，可有效地遮蔽槲黃素配糖體之苦味。 From the results of Table 2, it was found that the bitterness of the flavonoid glycoside can be effectively masked by blending a certain amount or more of the imidazole peptide.

實施例3 Example 3

於含槲黃素配糖體之組成物中，進行探討適合遮蔽槲黃素配糖體之異味的組成及摻合比例。具體而言，試驗作為遮蔽槲黃素配糖體之異味時的成分之水系溶劑咪唑胜肽含有物、糊精。 In the composition containing the flavonoid glycoside, the composition and blending ratio suitable for masking the odor of the flavonoid glycoside are investigated. Specifically, an aqueous solvent imidazole peptide-containing substance or dextrin which is a component which masks the odor of the flavonoid glycoside is tested.

(材料) (material)

使用的材料如下所述。 The materials used are as follows.

(1)槲黃素配糖體：San’emikku P15(三榮源F‧F‧I製、含槲黃素配糖體15%) (1) quercetin glycoside: San’emikku P15 (Sanrongyuan F‧F‧I, containing quercetin glycoside 15%)

(2)咪唑胜肽A：水系溶劑萃取咪唑胜肽含有物：MARINE ACTIVE 10(燒津水產化學製、含甲肌肽10%、在柴魚之熱水萃取物中加入糊精的粉末) (2) Imidazole peptide A: aqueous solvent extraction of imidazole peptides: MARINE ACTIVE 10 (manufactured by Yaizu Aquatic Chemicals, containing 10% of carnosine, a powder of dextrin added to the hot water extract of the fish)

(3)咪唑胜肽B：水系溶劑萃取咪唑胜肽含有物：含甲肌肽之鮭魚萃取物(Maruhanichiro食品製、含甲肌肽30%、在鮭魚之熱水萃取物中加入糊精的粉末) (3) Imidazole peptide B: aqueous solvent extraction of imidazole peptides: carp extract containing carnosine (Maruhanichiro food, 30% containing carnosine, dextrin powder added to hot water extract of squid)

(4)咪唑胜肽C：水系溶劑萃取咪唑胜肽含有物：CBEX-P(Nippon Meat Packers製、含有甲肌肽與肌肽之合計量為15%、在雞胸肉之熱水萃取物中加入糊精之粉末) (4) Imidazole peptide C: aqueous solvent extraction Imidazole peptide containing: CBEX-P (Nippon Meat Packers, containing a total of 15% of mesin and carnosine, add dextrin in hot water extract of chicken breast Powder)

(評估方法) (evaluation method)

調製使上述槲黃素配糖體或各種遮蔽成分以表3所示之組成摻合的混合粉末。此時，使槲黃素配糖體與咪唑胜肽(甲肌肽‧肌肽)如表中所試之各比例進行調整。使6名試驗人員經口攝取所調製的混合粉末1g與水，且以下述基準進行評估來自槲黃素配糖體之苦味強度。 A mixed powder in which the above-described quercetin glycoside or various masking components were blended in the composition shown in Table 3 was prepared. At this time, the ratios of the quercetin glycoside and the imidazole peptide (carnosine ‧ carnosine) were adjusted as shown in the table. Six testers were orally ingested 1 g of the prepared mixed powder and water, and the bitterness intensity derived from the flavonoid glycoside was evaluated on the basis of the following criteria.

以僅槲黃素配糖體之苦味強度為1分，以1~5分進行評估。 The bitterness intensity of only the quercetin glycoside was 1 point, and it was evaluated by 1 to 5 points.

1分：「感覺與槲黃素配糖體同等強烈的苦味」 1 point: "I feel the same bitter taste as the flavonoid glycoside"

2分：「感覺弱的苦味」 2 points: "Feel weak bitterness"

3分：「感覺稍弱的苦味」 3 points: "I feel a bit weaker bitterness"

4分：「幾乎感覺不到苦味」 4 points: "I can hardly feel bitterness."

5分：「完全沒有感覺到苦味」 5 points: "I don't feel bitter at all."

集計6名試驗人員之評估，分數之平均值未達1.5時為×，1.5分以上、未達2.5分時為△，2.5分以上為○。結果如表3所示。 The evaluation of six testers was performed. When the average value of the scores was less than 1.5, it was ×, 1.5 points or more, when it was less than 2.5 points, it was △, and when it was 2.5 points or more, it was ○. The results are shown in Table 3.

由表3之結果可知，藉由以1：25至1：50摻合咪唑胜肽與槲黃素配糖體，可有效地遮蔽苦味。另外，即使提高咪唑胜肽之摻合比例，仍可期待苦味之遮蔽效果。 From the results of Table 3, it was found that the bitterness was effectively masked by blending the imidazole peptide with the quercetin glycoside at 1:25 to 1:50. Further, even if the blending ratio of the imidazole peptide is increased, the shading effect of bitterness can be expected.

實施例4 Example 4

量取有效成分換算量之槲黃素配糖體90mg((San’emikkuP15)(含槲黃素配糖體15%)600mg))、及可期待遮蔽苦味效果之咪唑胜肽10mg(MARINE ACTIVE 10(含甲肌肽10%)100mg)，另外，量取含有維生素D 5μg、蛋白多醣1mg(蛋白多醣F(含蛋白多醣20%)5mg)。在此等原料中摻合賦形劑之纖維素、硬脂酸鈣、氧化矽進行打錠，製得本發明之錠劑。實施打錠用混合粉末及錠劑之官能評估。結果，皆確認沒有苦味。藉由咪唑胜肽之槲黃素配糖體的苦味遮蔽效果，即使為混合粉末狀態，仍可確認。此外，為錠劑時，與不含咪唑胜肽之錠劑相比時，具有遮蔽效果。 The amount of the active ingredient-converted flavonoid glycoside 90 mg ((San'emikku P15) (containing quercetin glycoside 15%) 600 mg)), and the imidazole peptide 10 mg (MARINE ACTIVE 10) which can be expected to mask the bitterness effect (containing 10% of carnosine) 100 mg), and 5 μg of vitamin D and 1 mg of proteoglycan (5 mg of proteoglycan F (20% containing proteoglycan)) were weighed. The tablets of the present invention are prepared by blending the cellulose, calcium stearate, and cerium oxide of the excipients into the raw materials. Perform functional evaluation of mixed powders and tablets for tableting. As a result, it was confirmed that there was no bitterness. The bitterness shielding effect of the quercetin glycoside of the imidazole peptide can be confirmed even in the state of the mixed powder. Further, in the case of a tablet, it has a shielding effect when compared with a tablet containing no imidazole peptide.

咪唑胜肽之槲黃素配糖體所致的苦味遮蔽效果，容易推測不論是混合粉末、或飲料或錠劑等其他形態皆相同。 The bitterness shielding effect by the quercetin glycoside of the imidazole peptide is easily estimated to be the same in any other form such as a mixed powder or a beverage or a tablet.

實施例5 Example 5

於含槲黃素配糖體之組成物中，進行探討適合遮蔽槲黃素配糖體之異味的組成及摻合比例。 In the composition containing the flavonoid glycoside, the composition and blending ratio suitable for masking the odor of the flavonoid glycoside are investigated.

量取有效成分換算量之槲黃素配糖體90mg((San’emikkuP15)(含槲黃素配糖體15%) 600mg))、及可期待苦味遮蔽效果之咪唑胜肽10mg(MARINE ACTIVE 10(含甲肌肽10%)100mg)。另外，量取含有維生素D 5μg、蛋白多醣1mg(蛋白多醣F(含蛋白多醣20%)5mg)、葡糖胺鹽酸鹽1200mg、鯊魚軟骨萃取物(含硫酸軟骨素45mg、II型膠原蛋白45mg)、II型膠原蛋白胜肽45mg之原料。 The amount of the active ingredient converted to the flavonoid glycoside 90mg ((San’emikkuP15) (containing 15% of the flavonoid glycoside) 600 mg)), and 10 mg of imidazole peptide (MARINE ACTIVE 10 (containing carnosine 10%) 100 mg) which can be expected to have a bitterness shielding effect. In addition, weighed 5 μg of vitamin D, 1 mg of proteoglycan (5 mg of proteoglycan F (20% containing proteoglycan)), 1200 mg of glucosamine hydrochloride, and shark cartilage extract (containing chondroitin sulfate 45 mg, type II collagen 45 mg) ), a type II collagen peptide 45mg of raw materials.

(評估方法) (evaluation method)

調製以表4所示之組成摻合各原料的混合粉末。此時，以表中所示之各比例調整槲黃素配糖體與咪唑胜肽(甲肌肽‧肌肽)。使6名試驗人員經口攝取所調製的混合粉末1g與水，且以下述基準進行評估來自槲黃素配糖體之苦味強度。另外，在此等原料中摻合賦形劑之纖維素、硬脂酸鈣、氧化矽進行打錠，製得本發明之錠劑。實施打錠用混合粉末及錠劑之官能評估。 The mixed powder of each raw material was blended in the composition shown in Table 4. At this time, the flavonoid glycoside and the imidazole peptide (carnosine ‧ carnosine) were adjusted in the respective ratios shown in the table. Six testers were orally ingested 1 g of the prepared mixed powder and water, and the bitterness intensity derived from the flavonoid glycoside was evaluated on the basis of the following criteria. Further, in these raw materials, cellulose, calcium stearate, and cerium oxide, which are mixed with an excipient, are subjected to tableting to obtain a tablet of the present invention. Perform functional evaluation of mixed powders and tablets for tableting.

以僅槲黃素配糖體之苦味強度為1分，以1~5分進行評估。 The bitterness intensity of only the quercetin glycoside was 1 point, and it was evaluated by 1 to 5 points.

1分：「感覺與槲黃素配糖體同等的強烈苦味」 1 point: "I feel the same strong bitterness as the flavonoid glycoside"

2分：「感覺弱的苦味」 2 points: "Feel weak bitterness"

3分：「感覺稍弱的苦味」 3 points: "I feel a bit weaker bitterness"

4分：「幾乎感覺不到苦味」 4 points: "I can hardly feel bitterness."

5分：「完全沒有感覺到苦味」 5 points: "I don't feel bitter at all."

集計6名試驗人員之評估，分數之平均值未達1.5時為×，1.5分以上、未達2.5分時為△，2.5分以上為○。 結果如表4所示。 The evaluation of six testers was performed. When the average value of the scores was less than 1.5, it was ×, 1.5 points or more, when it was less than 2.5 points, it was △, and when it was 2.5 points or more, it was ○. The results are shown in Table 4.

由表4之結果可知，咪唑胜肽之槲黃素配糖體所致的苦味遮蔽效果，即使各自添加維生素D、蛋白多醣、葡糖胺鹽酸鹽、硫酸軟骨素、膠原蛋白時，仍沒有減弱的效果。然而，於摻合全部的原料時，仍可確認其遮蔽效果。因而，苦味之遮蔽效果，在混合表記的原料時皆可發揮。 From the results of Table 4, it is known that the bitterness shielding effect by the quercetin glycoside of the imidazole peptide is not even when vitamin D, proteoglycan, glucosamine hydrochloride, chondroitin sulfate, and collagen are added, respectively. Attenuated effect. However, when all of the raw materials were blended, the shading effect was confirmed. Therefore, the shading effect of bitterness can be exerted when mixing the raw materials of the watch.

另外，藉由本發明而得的錠劑，與不含咪唑胜肽之錠劑相比時，可確認其遮蔽效果。而且，咪唑胜肽之槲黃素配糖體所致的苦味遮蔽效果，可推測為混合粉末或飲料或錠劑等其他形態時皆同等。 Further, when the tablet obtained by the present invention is compared with a tablet containing no imidazole peptide, the shielding effect can be confirmed. Further, the bitterness shielding effect by the quercetin glycoside of the imidazole peptide is presumed to be equivalent to other forms such as a mixed powder or a beverage or a tablet.

〔產業上之可利用性〕 [Industrial Applicability]

藉由本發明，可提供改善起因於槲黃素配糖體之苦味的組成物。特別是於肌力降低的中高年齡以上增加的社會 中，容易推測今後的需求亦會增高，而且，藉由組合此等來抑制苦味之發明，乃是劃時代之發明。 According to the present invention, a composition for improving the bitterness of the flavonoid glycoside can be provided. Especially in the society where the middle and high ages of muscle strength decrease In the meantime, it is easy to speculate that the future demand will also increase, and it is an epoch-making invention to combine the suppression of the invention of bitterness.

Claims (7)

一種固體製劑，其係含有咪唑胜肽與酵素處理芸香素(rutin)之固體製劑，其中咪唑胜肽與酵素處理芸香素之重量比為1：20~50：1。 A solid preparation comprising a solid preparation of an imidazole peptide and an enzyme-treated rutin, wherein the weight ratio of the imidazole peptide to the enzyme-treated rutin is 1:20 to 50:1. 如請求項1之固體製劑，其中進一步含有由維生素D、蛋白多醣(proteoglycan)、葡糖胺類、硫酸軟骨素及膠原蛋白所成群中所選擇之至少1種。 The solid preparation according to claim 1, which further comprises at least one selected from the group consisting of vitamin D, proteoglycan, glucosamine, chondroitin sulfate, and collagen. 如請求項2之固體製劑，其中膠原蛋白為II型膠原蛋白。 The solid preparation of claim 2, wherein the collagen is type II collagen. 如請求項1至3中任一項之固體製劑，其係錠劑或顆粒劑。 A solid preparation according to any one of claims 1 to 3, which is a tablet or granule. 如請求項1至3中任一項之固體製劑，其係機能性食品。 The solid preparation according to any one of claims 1 to 3, which is a functional food. 一種含有酵素處理芸香素之固體製劑的製造方法，其係包含在含酵素處理芸香素之固體製劑中摻合咪唑胜肽，使咪唑胜肽與酵素處理芸香素之重量比成為1：20~50：1。 A method for producing a solid preparation containing an enzyme-treated rutin, which comprises blending an imidazole peptide in a solid preparation containing an enzyme-treated rutin, so that the weight ratio of the imidazole peptide to the enzyme-treated rutin is 1:20-50 :1. 一種含有酵素處理芸香素之固體製劑之香味改善方法，其特徵為摻合咪唑胜肽，使咪唑胜肽與酵素處理芸香素之重量比成為1：20~50：1。 A method for improving the flavor of a solid preparation containing an enzyme-treated rutin, characterized in that the imidazole peptide is blended so that the weight ratio of the imidazole peptide to the enzyme-treated rutin is 1:20 to 50:1.
TW102106731A 2012-03-08 2013-02-26 Contains the composition of imidazole peptides and quercetin glycosides TWI517793B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012051946 2012-03-08

Publications (2)

Publication Number Publication Date
TW201347681A TW201347681A (en) 2013-12-01
TWI517793B true TWI517793B (en) 2016-01-21

Family

ID=49116178

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102106731A TWI517793B (en) 2012-03-08 2013-02-26 Contains the composition of imidazole peptides and quercetin glycosides

Country Status (5)

Country Link
JP (1) JP5324000B1 (en)
CN (1) CN103300278B (en)
HK (1) HK1185230A1 (en)
TW (1) TWI517793B (en)
WO (1) WO2013132668A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2996704T3 (en) 2013-05-14 2021-06-28 Mars, Incorporated Joint care composition
JP6310708B2 (en) * 2014-01-28 2018-04-11 花王株式会社 Solid composition
GB201414910D0 (en) * 2014-05-23 2014-10-08 Mars Inc Composition
JP6676292B2 (en) * 2015-06-23 2020-04-08 三栄源エフ・エフ・アイ株式会社 Oral composition
WO2017180127A1 (en) * 2016-04-14 2017-10-19 Lucey Michael Combinational compositions and methods of use thereof
JP7134607B2 (en) * 2016-08-25 2022-09-12 大正製薬株式会社 tablet
JP2018090640A (en) * 2018-03-16 2018-06-14 花王株式会社 Solid composition
CN108926506B (en) * 2018-09-27 2022-02-25 中国农业科学院麻类研究所 Method for extracting flavonol components in jute leaves, extract and application thereof
SG11202107999PA (en) * 2019-02-20 2021-09-29 Suntory Holdings Ltd Protein-containing oral composition and method for improving flavor of protein-containing oral composition
CN115023150B (en) * 2019-12-17 2024-04-26 三得利控股株式会社 Composition for promoting synthesis of chondroitin sulfate
JP6956846B1 (en) * 2020-12-17 2021-11-02 ダイドーグループホールディングス株式会社 Low back pain improver and trunk muscle strength improver
JP7080388B1 (en) 2021-10-29 2022-06-03 ダイドーグループホールディングス株式会社 An agent for improving dynamic balance in gait function, an agent for reducing anxiety about falls, and an agent for improving gait function for people with decreased mobility.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01110616A (en) * 1987-10-22 1989-04-27 Naoki Suzuki Bath agent
DE69312547T2 (en) * 1992-04-02 1998-01-08 Hayashibara Biochem Lab Process for improving the taste of a spruce extract and product obtained for oral use
JPH07265008A (en) * 1994-03-29 1995-10-17 Ajinomoto Co Inc Agent for imparting good body
JPH0899861A (en) * 1994-09-30 1996-04-16 Kose Corp Skin external agent
DE4444238A1 (en) * 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
JP3416104B2 (en) * 1999-12-20 2003-06-16 雪印食品株式会社 Method for enhancing antioxidant ability of food and antioxidant enhancer for food
JP2002101843A (en) * 2000-10-02 2002-04-09 Ajinomoto Co Inc Sweetener composition for boiled food
JP2004059522A (en) * 2002-07-30 2004-02-26 Fancl Corp Long-acting rutin preparation
JP2005006615A (en) * 2003-06-17 2005-01-13 Crescendo Corporation Chabushi
JP2006158274A (en) * 2004-12-06 2006-06-22 National Agriculture & Food Research Organization Sprout using f. tataricum grain
JP4635159B2 (en) * 2005-09-05 2011-02-16 独立行政法人農業・食品産業技術総合研究機構 Edible plant body containing GABA in high concentration and method for producing the same
US20080193591A1 (en) * 2005-12-26 2008-08-14 Yaizu Suisankagaku Industry Co., Ltd. Taste Improving Agent for Food and Beverage Containing Potassium Chloride, Process for Producing Food and Beverage Containing Potassium Chloride and Food and Beverage Containing Potassium Chloride Produced by the Process
JP2007197363A (en) * 2006-01-26 2007-08-09 Beta Shokuhin Kk Nutritional supplement
US20090214712A1 (en) * 2008-02-21 2009-08-27 The Coca Cola Company Milk-Based Beverage and Method for Preventing Off-Flavors in a Milk-Based Beverage
CN102105154B (en) * 2008-07-30 2013-03-27 三得利控股株式会社 Preparation for oral administration comprising water-extracted chondroitin sulfate and quercetin glycoside
WO2011130705A1 (en) * 2010-04-15 2011-10-20 Chromocell Corporation Compounds, compositions, and methods for reducing or eliminating bitter taste

Also Published As

Publication number Publication date
TW201347681A (en) 2013-12-01
CN103300278B (en) 2015-01-28
CN103300278A (en) 2013-09-18
WO2013132668A1 (en) 2013-09-12
JPWO2013132668A1 (en) 2015-07-30
JP5324000B1 (en) 2013-10-23
HK1185230A1 (en) 2014-02-14

Similar Documents

Publication Publication Date Title
TWI517793B (en) Contains the composition of imidazole peptides and quercetin glycosides
CN101132786B (en) Salts, addition compounds and complex compounds of guanidinoacetic acid
JP4738464B2 (en) Adiponectin secretion promoting food and drink
KR20120097516A (en) Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages
CN108697685A (en) Containing moracin, Phellinus copper G or the root bark of white mulberry, the prevention of muscle disease and treatment is used or muscular function improvement composition
JPWO2010013551A1 (en) Formulation for oral administration containing chondroitin sulfate-containing cartilage aqueous solvent extract and quercetin glycoside
JP6086953B2 (en) AMPK activator
KR101842948B1 (en) Composition comprising Decanal or as active ingredients for Preventing or treating muscle disease
CN107530320A (en) Muscle fatization suppression composition
CA2692371A1 (en) Anti-fatigue composition
CN108135955A (en) muscle-building agent
JP2011121926A (en) Composition including at least either one of protopanaxatriol and protopanaxadiol
KR101809379B1 (en) Composition comprising Diosmin or as active ingredients for Preventing or treating muscle disease
JP4253296B2 (en) Health beauty food
JP5176418B2 (en) Branched chain amino acid beverage
JP6127545B2 (en) Method for producing anti-obesity composition comprising complex of gallate catechin and protein and caffeine
JP2002265359A (en) Kainic acid type glutamate receptor-shielding agent, ampa type glutamate receptor shielding agent, brain- protecting agent and food or drink having brain- protecting function
JP4648309B2 (en) Proanthocyanidin water-soluble conjugate and composition containing the same
KR101610894B1 (en) Taste-masked granules containing vitamin C
CN115867289A (en) Composition containing NR and/or NMN and sesamin
CN103108556A (en) Ingredients derived from sphaeranthus indicus
WO2007116980A1 (en) Suppressor of increase in blood glucose level
JP5702514B2 (en) Stabilization method for photodegradation of lutein
KR20010009653A (en) Composition for treating sexual dysfunction
Aburawi et al. EFFECT OF BLACK TEA PREPARATION ON VITAMIN C ABSORPTION IN ALBINO RAT ILEUM USING EVERTED GUT SAC TECHNIQUE.